tradingkey.logo
tradingkey.logo
Buscar

Fulgent Genetics Inc

FLGT
Añadir a la lista de seguimiento
20.850USD
+0.030+0.14%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
601.54MCap. mercado
PérdidaP/E TTM

Más Datos de Fulgent Genetics Inc Compañía

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Información de Fulgent Genetics Inc

Símbolo de cotizaciónFLGT
Nombre de la empresaFulgent Genetics Inc
Fecha de salida a bolsaSep 28, 2016
Director ejecutivoHsieh (Ming)
Número de empleados1313
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 28
Dirección4399 Santa Anita Ave
CiudadEL MONTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91731
Teléfono16263500537
Sitio Webhttps://www.fulgentgenetics.com/
Símbolo de cotizaciónFLGT
Fecha de salida a bolsaSep 28, 2016
Director ejecutivoHsieh (Ming)

Ejecutivos de Fulgent Genetics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
15.54K
-16.55%
Ms. Melanie Solomon
Ms. Melanie Solomon
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Fulgent Genetics Inc?

Los cinco principales accionistas de Fulgent Genetics Inc son: Mr. Ming Hsieh

¿Cuántas instituciones poseen acciones de Fulgent Genetics Inc (FLGT)?

A fecha de 2026Q1, 430 instituciones poseen acciones de Fulgent Genetics Inc, con un valor de mercado combinado de aproximadamente 18.21M, lo que representa el 64.11% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1416587.00.

¿Cuál es la mayor fuente de ganancias de Fulgent Genetics Inc?

El 2026Q1, el segmento empresarial Institutional generó la ganancia más alta para Fulgent Genetics Inc, ascendiendo a 184.60M y representando el 57.21% de la ganancia total.